Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors
Open Access
- 25 June 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 72 (2), 249-253
- https://doi.org/10.1093/cid/ciaa849
Abstract
The pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has tremendous consequences for our societies. Knowledge of the seroprevalence of SARS-CoV-2 is needed to accurately monitor the spread of the epidemic and to calculate the infection fatality rate (IFR). These measures may help the authorities to make informed decisions and adjust the current societal interventions. The objective was to perform nationwide real-time seroprevalence surveying among blood donors as a tool to estimate previous SARS-CoV-2 infections and the population based IFR. Danish blood donors aged 17–69 years giving blood April 6 to May 3 were tested for SARS-CoV-2 immunoglobulin M and G antibodies using a commercial lateral flow test. Antibody status was compared between geographical areas and an estimate of the IFR was calculated. The seroprevalence was adjusted for assay sensitivity and specificity taking the uncertainties of the test validation into account when reporting the 95% confidence intervals (CI). The first 20,640 blood donors were tested and a combined adjusted seroprevalence of 1.9% (CI: 0.8-2.3) was calculated. The seroprevalence differed across areas. Using available data on fatalities and population numbers a combined IFR in patients younger than 70 is estimated at 89 per 100,000 (CI: 72-211) infections. The IFR was estimated to be slightly lower than previously reported from other countries not using seroprevalence data. The IFR is likely several fold lower than the current estimate. We have initiated real-time nationwide anti-SARS-CoV-2 seroprevalence surveying of blood donations as a tool in monitoring the epidemic.Funding Information
- Bestseller Foundation
This publication has 12 references indexed in Scilit:
- Estimates of the severity of coronavirus disease 2019: a model-based analysisThe Lancet Infectious Diseases, 2020
- The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and ApplicationAnnals of Internal Medicine, 2020
- Geographic Differences in COVID-19 Cases, Deaths, and Incidence — United States, February 12–April 7, 2020Morbidity and Mortality Weekly Report (MMWR), 2020
- Likelihood of survival of coronavirus disease 2019The Lancet Infectious Diseases, 2020
- Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019Clinical Infectious Diseases, 2020
- Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020Morbidity and Mortality Weekly Report (MMWR), 2020
- Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational studyThe Lancet Respiratory Medicine, 2020
- Socio-demographic characteristics of Danish blood donorsPLOS ONE, 2017
- Blood donation and blood donor mortality after adjustment for a healthy donor effectTransfusion, 2015
- T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected MiceJournal of Virology, 2010